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ABSTRACT
Background Anxiety disorder, one of the highly disabling, 
prevalent and common mental disorders, is known to be 
more prevalent in persons with type 2 diabetes mellitus 
(T2DM) than the general population, and the comorbid 
presence of anxiety disorders is known to have an impact 
on the diabetes outcome and the quality of life. However, 
the information on the type of anxiety disorder and its 
prevalence in persons with T2DM is limited.
Aims To assess the prevalence and correlates of anxiety 
disorder in people with type 2 diabetes in different 
countries.
Methods People aged 18–65 years with diabetes 
and treated in outpatient settings were recruited in 
15 countries and underwent a psychiatric interview 
with the Mini- International Neuropsychiatric Interview. 
Demographic and medical record data were collected.
Results A total of 3170 people with type 2 diabetes 
(56.2% women; with mean (SD) duration of diabetes 
10.01 (7.0) years) participated. The overall prevalence of 
anxiety disorders in type 2 diabetic persons was 18%; 
however, 2.8% of the study population had more than 
one type of anxiety disorder. The most prevalent anxiety 
disorders were generalised anxiety disorder (8.1%) 
and panic disorder (5.1%). Female gender, presence of 
diabetic complications, longer duration of diabetes and 
poorer glycaemic control (HbA1c levels) were significantly 
associated with comorbid anxiety disorder. A higher 
prevalence of anxiety disorders was observed in Ukraine, 
Saudi Arabia and Argentina with a lower prevalence in 
Bangladesh and India.
Conclusions Our international study shows that 
people with type 2 diabetes have a high prevalence of 
anxiety disorders, especially women, those with diabetic 
complications, those with a longer duration of diabetes 
and poorer glycaemic control. Early identification and 
appropriate timely care of psychiatric problems of people 
with type 2 diabetes is warranted.
InTRoduCTIon
Anxiety disorders are characterised by exces-
sive worries, hyperarousal states and fear, which 
are counterproductive and debilitating.1 The 
global prevalence of anxiety disorder in the 
general population is about 7.3% (4.8%–
10.9%),2 and it is one of the leading causes of 
disability with 390 disability- adjusted life years 
per 100 000 persons.3 Anxiety disorders mainly 
comprise generalised anxiety disorder (GAD), 
panic disorder, agoraphobia, social phobia, 
obsessive- compulsive disorder (OCD) and 
post- traumatic stress disorder (PTSD). Recent 
high- quality studies,4–9 including a systematic 
review,10 have reported a higher prevalence 
and incidence of anxiety disorders in people 
with type 2 diabetes mellitus compared with 
the general population. It has also been 
suggested that there may be a bidirectional 
relationship between these two disorder condi-
tions.11 12 Female sex, younger age, low socio-
economic status and concomitant chronic 
illnesses are particular vulnerability factors 
for developing anxiety disorders.5 13 14 The 
most prevalent anxiety disorders in people 
with diabetes mellitus are GAD (21%), social 
phobia (7%) and panic disorder (2.5%).15 A 
substantial proportion of people with diabetes 
also exhibit higher subsyndromal anxiety and 
elevated anxiety symptoms.10 14 16 In diabetes, 
anxiety is associated with poor glycaemic 
control,16–20 increased risk of diabetes- related 
complications, increased risk of stroke21 and 
poor quality of life,22 23 which may improve 
with anxiolytics and non- pharmacological 
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treatments.24–26 Hence, it is essential to identify and 
address anxiety in persons with diabetes early on, in order 
to reduce the burden of comorbid disease, improve blood 
glucose control and therefore reduce the risk of diabetes 
complications.
There are wide variations in the prevalence of anxiety 
disorders across countries and within, which could be 
due to heterogeneous study samples, the use of different 
assessment tools and even using different cut- off levels 
within the same scales. In addition, many studies have 
reported the presence of both elevated anxiety symp-
toms and the syndromal anxiety disorders with less clear 
distinction between them.14 16
More specifically, the prevalence of anxiety symp-
toms in patients with type 2 diabetes using the Hospital 
Anxiety and Depression Scale in Pakistan was reported 
to be around 57.9%,27 with a much lower prevalence of 
9% in Germany.28 In Saudi Arabia, the prevalence of 
psychiatric disorders in the general population is still 
unknown. However, the prevalences of primary anxiety 
disorders among inpatient and outpatient psychiatric 
patients in Saudi Arabia have been reported as 1.6% and 
16.3%, respectively.29 With regard to diabetes popula-
tions in Saudi Arabia (which has one of the highest prev-
alence rates of type 2 diabetes), studies have reported the 
prevalence of significant anxiety symptoms to be 28.5%, 
which was higher in women, those smoking, with a longer 
duration of diabetes and being unmarried.30 Another 
study in Saudi Arabia, using the Hamilton Anxiety Scale, 
reported a prevalence of 3.3% of people with diabetes 
compared with 5% of controls with no significant differ-
ence.31 Among hospitalised patients with type 2 diabetes 
50.6% were identified as suffering from anxiety which 
was independently associated with physical inactivity.9 
Approximately similar prevalence rates were observed 
in two studies of patients with type 2 diabetes, with phys-
ical inactivity and poor social support being explanatory 
factors.9 10
In Poland, a nationwide study conducted between 2010 
and 2011 on a large population of 10 081 persons aged 
18–64 showed the prevalence of different anxiety disor-
ders to be between 0.1% and 6.2%;32 however, there 
are no reports of anxiety in persons with diabetes. In 
contrast, one study in Russia observed a much higher rate 
of anxiety disorders of 60%.33 Diabetes- specific phobias 
(phobias of needles, blood, hypoglycaemia) were also 
observed in 1.7%.34 These studies have combined people 
with type 1 and type 2 diabetes so it is difficult to infer the 
exact prevalence and association of anxiety disorders in 
each of the subtypes of diabetes.
In a collaborative study across 15 countries differing in 
socioeconomic status, cultural background and levels of 
healthcare services, we aimed to study the prevalence and 
treatment of comorbid anxiety disorder in a large cohort 
of people with type 2 diabetes. The same study protocol 
was used across the countries which included both a clin-
ical interview and a screening instrument to detect clini-
cally significant anxiety.35
MeThodS
A full description of the protocol of the International 
Prevalence and Treatment of Diabetes and Depression 
(INTERPRET- DD) study used in the present study is 
provided in earlier papers.35 36 In brief, consecutive 
outpatient clinic attendees with type 2 diabetes, diag-
nostic criteria according to WHO criteria (random 
plasma glucose ≥11.1 mmol/L or fasting plasma 
glucose ≥7.0 mmol/L or 2- hour plasma glucose ≥11.1 
mmol/L), at each of the study sites were invited to 
participate in the study between September 2013 and 
May 2015. Site investigator teams were recruited from 
leading centres of excellence in each country, which 
included at least one psychiatrist and endocrinologist 
for each country. The treating physician/diabetolo-
gist in the diabetes clinic invited individuals to partic-
ipate in the study. Diabetes clinics were based in either 
secondary or tertiary care centres, depending on the 
facilities available in each country. However, from 
Pakistan, another centre from primary care was also 
included. The observations presented here pertain 
to the first cross- sectional assessment of the subjects 
during the first intake.
Inclusion/exclusion criteria
Full details of the eligibility criteria have been described 
elsewhere.35 36 In brief, the participants were adults (aged 
18–65 years) with type 2 diabetes diagnosed at least 12 
months before the point of contact at the diabetes outpa-
tient facilities. Detailed medical records and sociodemo-
graphic details of the participants were obtained.
A psychiatric interview was conducted by a trained inter-
viewer using the Mini- International Neuropsychiatric 
Interview (MINI, version 5 or version 6 depending on the 
current psychiatric practice at the study site).37 The MINI 
is a reliable diagnostic tool that has been widely used in a 
range of different populations, suitable for subjects with 
serious illness as well as in community surveys, and is in 
accordance with the Diagnostic and Statistical Manual 
of Mental Disorders Fifth Edition criteria.38 Individuals 
diagnosed with anxiety disorders were advised to consult 
their physician for further assessment and treatment. In 
the case of any psychiatric emergencies such as suicidal 
risk,the interviewing psychiatrist initiated immediate 
appropriate clinical care.
Statistical analysis
SPSS V.2339 was used to analyse the data. Comparative 
profiles of demographic and clinical variables between 
people with type 2 diabetes with and without anxiety 
disorder were examined using independent samples t- test 
or χ2 test as applicable.
ReSulTS
A total of 3170 people with type 2 diabetes (56.2% 
women; mean (SD) duration of diabetes 10.01 (7.0) 
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Figure 1 Flowchart of the sample recruitment.
years) participated (see figure 1). The mean (SD) age of 
the study population was 53.43 (9.52) years.
The prevalence of anxiety disorders in type 2 diabetes 
persons was 18% (table 1). The most common anxiety 
disorders were GAD (8.5%) and lifetime panic disorder 
(5.1%). More than one type of anxiety disorders were 
observed in 2.8% of the study population. Only 4% of 
the study subjects had more than one psychiatric disorder 
like dysthymia or major depressive episode.
Particularly Ukraine, Saudi Arabia and Argentina 
showed higher rates of anxiety disorders (72.7%, 52.2% 
and 37.6%, respectively) whereas prevalences were found 
to be lower/absent in India and Bangladesh (0.5% and 
0.0%, respectively) as shown in table 1. These differ-
ences were statistically different between the countries. 
However, it is not possible to compute these differences 
for different types of anxiety disorders in different coun-
tries due to small (or absent) numbers in many categories 
in different countries.
Female gender was positively associated with all anxiety 
disorders (table 2).
Presence of GAD (t=3.08, p=0.002) and current panic 
disorder (t=1.98, p=0.04) as well as lifetime panic disorder 
(t=2.21, p=0.027) were all significantly associated with 
poorer glycaemic control as indicated by HbA1c levels 
compared with participants without anxiety disorders 
(table 3).
Duration of diabetes was positively correlated with 
the presence of GAD (t=4.645, p=0.001), OCD (t=2.064, 
p=0.039) and PTSD (t=3.201, p=0.001) (table 4).
Those with anxiety disorders except OCD showed statis-
tically significantly higher rates of diabetic complications 
than those without anxiety disorders (table 5). The diabetic 
complications recorded were mainly in the form of diabetic 
nephropathy and neuropathy. Almost half the subjects 
had one or more diabetes- related medical complications 
as reported in our previous study on the same subject 
samples.35
dISCuSSIon
Main findings
In our study we observed a substantially high preva-
lence of anxiety disorder (18%) in people with type 
2 diabetes. The most prevalent anxiety disorders were 
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Table 2 Gender differences across anxiety disorders in people with diabetes
Gender
χ2 P value
Female
n (% of total sample)
Male
n (% of total sample)
GAD (current) 193 (6.1) 77 (2.4) 27.78 <0.001
Panic disorder (current) 80 (2.5) 40 (1.3) 5.43 0.020
Agoraphobia 84 (2.7) 26 (0.8) 18.71 <0.001
OCD 36 (1.1) 7 (0.2) 13.32 <0.001
Social phobia 60 (1.9) 21 (0.7) 10.71 <0.001
Panic disorder (lifetime) 118 (3.7) 43 (1.4) 19.96 <0.001
GAD, generalised anxiety disorder; OCD, obsessive- compulsive disorder.
Table 3 Diabetic control (HbA1c %) by anxiety disorders
HbA1c % in those with 
anxiety disorders
n (mean (SD))
HbA1c % in those without 
anxiety disorders
n (mean (SD))
T- test 
statistics P value 95% CI
GAD 215
(8.79 (2.45))
2074
(8.27 (2.36))
−3.08 0.002 0.86 to 0.19
Panic disorder (current) 109
(8.76 (2.05))
2179
(8.30 (2.39))
−1.98 0.040 0.90 to 0.00
Agoraphobia 98
(8.45 (2.21))
2192
(8.31 (2.380))
−0.52 0.580 0.61 to 0.34
OCD 39
(8.69 (2.27))
2251
(8.31 (2.38))
−0.99 0.320 1.13 to 0.37
Social phobia 73
(8.78 (2.32))
2217
(8.30 (3.28))
−1.70 0.088 1.03 to 0.72
Panic disorder (lifetime) 149
(8.73 (2.36))
2141
(8.29 (2.38))
−2.21 0.027 0.84 to 0.05
GAD, generalised anxiety disorder; OCD, obsessive- compulsive disorder.
found to be GAD and panic disorder. Some countries 
had statistically higher rates of anxiety disorders than 
others. However, whether these statistical differences 
reflect differences in the overall rates in these coun-
tries is difficult to comment as the general population 
prevalence of anxiety disorders in all the countries is 
not available. Female gender, the presence of diabetes 
complications, longer duration of diabetes and poorer 
glycaemic control were all observed to be correlates 
of anxiety disorders, however there was wide varia-
tion of occurrence of anxiety disorders across the 15 
countries studied. The predominance of anxiety disor-
ders in females with diabetes may be a reflection of 
the overall pattern for anxiety disorders. This study 
identified differences in the prevalence of anxiety 
symptoms, as well as the clinical diagnosis of anxiety 
disorders among the countries. Similar observations 
were described in the report on depressive disorders 
in diabetes mellitus, in this same sample group.35 
This may reflect differences in the acceptance/
stigma of acknowledging symptoms of psychological 
and emotional distress in different cultural groups. 
It is difficult to speculate whether the different rates 
can be attributed to between- country characteristics, 
as this aspect was not studied in detail.35 The exact 
ratio of anxiety disorders in the general population of 
each country was not available to derive any conclu-
sive inference about the effect of gender on occur-
rence of anxiety disorders in people with diabetes. We 
observed a high percentage of anxiety disorders in the 
Russian sample which may be caused by the relatively 
higher proportion of women in the sample, which was 
76.5%. The detection of anxiety disorders in women 
compared with men was higher, especially in agora-
phobia (16.3% vs 6.4%). The increased frequency of 
anxiety disorders in participants from Russia may be 
related to the high frequency of PTSD, which reached 
7.5%.
The findings of this study make an important contribu-
tion to the evidence of occurrence of anxiety disorders 
in people with type 2 diabetes. In particular, we have 
used the same methodology for identification across all 
the countries and so comparisons are more appropriate. 
Similar findings were reported in studies from the USA40 
and others on higher risk of development and prevalence 
of anxiety disorders in persons with diabetes.10 12 15 41 
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Table 4 Duration of diabetes by anxiety disorders
Yes
n (mean (SD))
No
n (mean (SD)) T- test statistics P value 95% CI
GAD 268 (11.91 (7.87)) 2884 (9.83 (6.90)) −4.64 <0.001 1.19 to 0.44
Panic disorder 
(current)
120 (10.83 (6.52)) 3031 (9.98 (7.03)) −1.29 0.194 0.43 to 0.65
Agoraphobia 109 (10.05 (6.86)) 3043 (10.01 (7.01)) 0.05 0.955 1.30 to 0.68
Social phobia 81 (10.32 (6.12)) 3071 (10.01 (7.03)) 0.39 0.694 1.23 to −0.31
OCD 43 (12.20 (7.45)) 3109 (9.98 (7.00)) −2.06 0.039 −0.11 to 1.07
Panic disorder 
(lifetime)
161 (10.59 (7.18)) 2992 (9.98 (7.00)) −1.06 0.287 0.50 to 0.56
GAD, generalised anxiety disorder; OCD, obsessive- compulsive disorder.
Table 5 Diabetes complications by anxiety disorder
Diabetic complication χ2 statistic P value
Yes
n (% of total sample)
No
n (% of total sample)
GAD (current) 154 (5.3) 93 (3.2) 9.21 0.002
Panic disorder 82 (2.8) 32 (1.1) 16.75 <0.001
Agoraphobia 69 (2.4) 39 (1.3) 5.21 0.022
Social phobia 52 (1.8) 25 (0.9) 6.56 0.010
OCD 26 (0.9) 15 (0.5) 1.76 0.185
Panic disorder (lifetime) 100 (3.4) 55 (1.9) 8.50 0.004
GAD, generalised anxiety disorder; OCD, obsessive- compulsive disorder.
However, there is wide variation in prevalence of anxiety 
disorders across studies which could be due to differences 
in methodology such as the tools used for assessment, 
ethnic background, cultural variation or diabetes- related 
factors.10
Like other studies,14 22 we have observed wide differ-
ences in rates of anxiety disorders across the 15 coun-
tries, with higher rates in countries such as Ukraine, 
Saudi Arabia and Argentina, and lower rates in coun-
tries such as India, Bangladesh and Pakistan. It is 
interesting to note that the rates of anxiety disorders 
in this study were lower than the World Mental Health 
Survey (WMHS) initiative42 in two countries, Germany 
and Italy, and markedly higher in another two coun-
tries, namely Ukraine and Mexico. In the clinical 
sample in this study, we would have expected higher 
rates compared with the general population sample 
in WMHS, but the findings do not indicate this consis-
tently. The differences between countries that we have 
observed could be speculated to be due to cultural 
differences in the reporting and experience of anxiety 
symptoms, possibly due to the stigma associated with 
having a mental health problem or due to the exten-
sive social support offered by families in some coun-
tries which may aid onset prevention. In addition, 
anxiety disorders in the general population have been 
reported to be less prevalent in the Indo/Asian coun-
tries than in the rest of the world,13 which supports 
our findings. A South American country (Brazil) has 
reported a much higher prevalence of GAD and panic 
disorder compared with the prevalence we observed 
in Argentina. This difference could be due to differ-
ences in diabetes duration (the Brazilian study only 
included people with more than 5 years of diabetes 
compared with the current study in which participants 
are included with at least 1 year of diabetes). In our 
study, duration of diabetes was a significant factor 
associated with anxiety disorders.
The results in the sample of patients from Poland show 
a strikingly higher prevalence of anxiety disorders in 
persons with type 2 diabetes in comparison to the general 
population. The prevalence of social phobia was over 
three times higher, GAD almost 10 times higher, panic 
disorder almost 14 times higher and agoraphobia almost 
19 times higher in persons with type 2 diabetes when 
compared with the most recent data from a large sample 
of the general population.32 With the current method-
ology, it is difficult to speculate on the possible reasons 
for this observation.
Our findings of a relationship between symptoms 
of anxiety and other physical comorbidities, along 
with poorer glycaemic control, support the findings 
of other countries mentioned above. In our previous 
report on this study sample, insulin use was reported 
by 41.8%, and 50.8% of subjects reporting one or more 
complications.35
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limitations
As in other studies, the present study also has some limita-
tions. First, the severity of the anxiety disorders was not 
measured. Second, details about the use of psychotropic 
medications for the persons with clinically significant 
anxiety which could have provided an indirect measure 
of severity of the symptoms were not available. Third, 
details about insulin requirements for the management 
of diabetes could have given information as to whether 
the psychological distress related to use of insulin has an 
impact on the anxiety symptoms.43 Although the assess-
ments and interviews were conducted by trained and 
qualified interviewers, the inter- rater reliability between 
the interviewers was not attempted due to the location of 
centres across the 15 countries. In our follow- up study, we 
will be able to examine the longitudinal associations of the 
use of psychotropic medications or non- pharmacological 
management of anxiety disorders on glycaemic control. 
Fourth, because the present study took place in specialty 
clinics, which may not be representative of the wider 
population of people with diabetes, the prevalence rates 
in the present study cannot be generalised to the wider 
diabetes population.
Implications
The INTERPRET- DD study has a number of strengths. 
It was a collaborative study of the prevalence of anxiety 
disorders in people with type 2 diabetes, carried out at the 
same time using the same protocol in 15 different coun-
tries. This study included more than 3000 people with 
a clinical diagnosis of type 2 diabetes,35 36 and is meth-
odologically strong with the use of a reliable diagnostic 
tool for identifying anxiety disorders implemented by 
trained interviewers. In addition, the investigators in each 
country ensured that the diagnostic tools were culturally 
applicable through a series of discussions and testing by a 
range of healthcare professionals and people with type 2 
diabetes, which focused on the meaning of terms as well 
as language.
ConCluSIon
This report presents the cross- sectional findings on the 
occurrence of anxiety disorders, hence, it is difficult to 
comment on whether the anxiety disorder is a complica-
tion or sequelae of diabetes, or just a comorbid psychiatric 
condition. It is not possible to comment on which anxiety 
disorders were present prior to diagnosis of diabetes, 
and which were a consequence of having diabetes. The 
result of our prospective follow- up study is likely to shed 
light on this aspect. It is essential to pay additional atten-
tion to mental health issues such as anxiety in persons 
with diabetes to ensure better quality of life22 and better 
glycaemic control,44 and to lessen the burden of diabetes- 
related complications.21 45 It is likely that anxiety may be 
a protective factor for diabetes complications as anxious 
people may consult more for minor symptoms and 
ailments.46
Anxiety disorder was observed in 18% of people with 
type 2 diabetes. Factors associated with higher preva-
lence of anxiety disorders were female gender, longer 
duration of diabetes, more diabetes complications and 
poorer diabetic control. The International Diabetes 
Federation recommends regular screening for psycho-
logical problems such as depression,47 and the findings 
of this present study extend this to anxiety. Hence, it is 
important to identify and address the comorbid anxiety 
in persons with diabetes at the earliest in order to 
offer psychological interventions which could improve 
diabetic control, so reducing the risk of developing 
diabetes complications which have negative conse-
quences for quality of life.
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